Stay updated with breaking news from Arcus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 7, 2023
FinancialContent fully hosted finance channel
FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Jun 3, 2023--
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy –– Re...
FinancialContent fully hosted finance channel